Milan, Italy

Carlo Confalconieri

This inventor holds 1 USPTO granted patent. Top assignee: Farmitalia Carlo Erba. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Carlo Confalconieri: Innovator in Antitumor Solutions

Introduction

Carlo Confalconieri is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of injectable solutions for cancer treatment. His work focuses on enhancing the efficacy and safety of antitumor therapies.

Latest Patents

Confalconieri holds a patent for "Injectable ready-to-use solutions containing an antitumor anthracycline." This invention provides a sterile, pyrogen-free solution of an anthracycline glycoside, specifically doxorubicin. The solution is designed to be physiologically acceptable and has a pH range of 2.5 to 6.5. This innovation is particularly beneficial for the injection administration of anthracycline glycoside drugs in treating both human and animal tumors.

Career Highlights

Carlo Confalconieri is associated with Farmitalia Carlo Erba, a company known for its advancements in pharmaceutical products. His work has contributed to the development of effective cancer treatments, showcasing his commitment to improving patient outcomes.

Collaborations

Confalconieri has collaborated with notable colleagues, including Diego Oldani and Gaetano Gatti. These partnerships have fostered innovation and have been instrumental in advancing their shared goals in pharmaceutical research.

Conclusion

Carlo Confalconieri's contributions to the field of antitumor solutions highlight his role as a key innovator in pharmaceuticals. His patent for injectable solutions represents a significant advancement in cancer treatment, demonstrating the impact of his work on healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…